The Efficacy of Xuebijing Injection on Sepsis

• Status: Completed
• Trial end date: 2020-01-08
• Target enrollment: 0
• Participant gender: All

Summary

The Efficacy of Xuebijing Injection in Adult Patients with Sepsis

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Southeast University, China
• Collaborators: National Health and Family Planning Commission, P.R.China; Tianjin Chasesun Pharmaceutical Co., LTD

Criteria

Inclusion Criteria:

Patients will be eligible for inclusion if all of the inclusion criteria are met

1. Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of Intensive Care Medicine (ESICM)

2. 18≤ age ≤75years

3. 2 ≤SOFA ≤13

4. obtain informed consent

Exclusion Criteria:

1. Diagnosis of sepsis for more than 48 h;

2. Pregnant and lactating women;

3. Severe primary disease including unrespectable tumours, blood diseases and Human Immunodeficiency Virus (HIV);

4. Severe liver and kidney dysfunction (single liver or kidney SOFA score ≥ 3 points);

5. Use of an immunosuppressant or having an organ transplant within the previous 6 months;

6. Participating in other clinical trials in the previous 30 days.